The University of Osaka · 생화학·유전·분자생물학
Fuminori Sakurai 교수의 연구실은 바이러스 기반 유전자 치료 및 종양 유도 온콜리틱 바이러스의 면역 활성화 메커니즘을 중심으로 연구를 진행하고 있습니다. 특히 아데노바이러스 벡터의 효율적 전달 체계 개발과 간염 바이러스(HBV)의 병변 모델링을 위한 induced pluripotent stem cell 유래 간세포 모델 구축에 주력하고 있습니다. 또한 암 미세환경 내 면역 억제 세포(MDSCs)를 타겟으로 한 온콜리틱 바이러스 치료 전략의 기전 규명을 목표로 하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
We have recently developed a replication-defective, recombinant adenovirus (Ad) vector composed of the whole Ad serotype 35 (Ad35), a member of subgroup B. We describe herein the in vitro and in vivo gene transfer properties of Ad35 vector in comparison with Ad serotype 5 (Ad5) and the Ad5F35 vector, which is a fiber-substituted Ad5 vector containing Ad35 fiber proteins. In vitro, Ad35 vector efficiently transduced not only human CAR-positive cells but also CAR-negative cells. Following intraven
In order to understand the life cycle of hepatitis B virus (HBV) and to develop efficient anti-HBV drugs, a useful in vitro cell culture system which allows HBV infection and recapitulates virus-host interactions is essential; however, pre-existing in vitro HBV infection models are often problematic. Here, we examined the potential of human induced-pluripotent stem (iPS) cell-derived hepatocyte-like cells (iPS-HLCs) as an in vitro HBV infection model. Expression levels of several genes involved
Oncolytic reovirus, which possesses 10 segments of dsRNA genome, mediates antitumor effects via not only virus replication in a tumor cell-specific manner, but also activation of antitumor immunity; however, the mechanism(s) of reovirus-induced activation of antitumor immunity have not been fully elucidated. Recent studies have demonstrated that overcoming an immunosuppressive environment in tumor-bearing hosts is important to achieve efficient activation of antitumor immunity. Among the various
